Skip to main content
main-content

01.12.2017 | Research article | Ausgabe 1/2017 Open Access

BMC Cancer 1/2017

High lymphatic vessel density and presence of lymphovascular invasion both predict poor prognosis in breast cancer

Zeitschrift:
BMC Cancer > Ausgabe 1/2017
Autoren:
Song Zhang, Dong Zhang, Mingfu Gong, Li Wen, Cuiwei Liao, Liguang Zou
Wichtige Hinweise

Electronic supplementary material

The online version of this article (doi:10.​1186/​s12885-017-3338-x) contains supplementary material, which is available to authorized users.
Abbreviations
CI
Confidence interval
DFS
Disease-free survival
H&E
Hematoxylin and eosin
HR
Hazard ratio
OS
Overall survival

Background

Breast cancer is one of the most common malignant tumors in females. Prognostic factors are helpful in clinical management and have the potential to improve the disease-free survival (DFS) and overall survival (OS) in breast cancer [ 1]. Several independent risk factors for survival have been identified, including tumor size, histological grade, nodal status, hormone receptor status, and HER-2 status [ 2, 3]. However, these risk factors are insufficient to fully determine an individual’s prognosis. More risk factors are needed to be explored.
Lymphatic vessel was formerly considered as a passive participant in tumor metastasis and regarded mainly as a transportation channel for tumor cells. Now, it appears that lymphatic vessel provides a safe route for tumor cells dissemination, because of the discontinuous structure of the lymphatic basement membrane, an ultraminiature shear stress, and a high concentration of hyaluronic acid [ 4]. Even so, it is still uncertain that whether the high lymphatic vessel density is a necessary condition for tumor metastasis. Many studies have demonstrated the unfavorable prognostic value of lymphatic vessel density in primary breast cancer [ 5, 6]. However, Zhang et al. [ 7] showed that lymphovascular invasion, but not lymphangiogenesis, was correlated with lymph node metastasis and poor prognosis in young breast cancer patients. Other studies found that the lymphatic vessel density in the lymph node metastasis negative group even was higher than that of the positive group in primary breast cancer [ 8, 9]. Therefore, a meta-analysis study is needed to pool the results to clarify the prognostic value of lymphatic vessel density in breast cancer.
Lymphatic metastasis contains a series of sequential processes, such as tumor associated lymphangiogenesis, lymphovascular invasion, implantation of cancer cells in regional lymph nodes, and proliferation of micrometastasis in distant organs [ 10]. Lymphovascular invasion, infiltration of tumor cells into lymphatic vessels, represents a high invasion feature of breast tumor cells. Determined by hematoxylin and eosin (H&E) staining in past time, lymphovascular invasion was widely investigated and showed a correlation with the clinicopathological outcomes of breast cancer [ 11, 12]. At present, lymphatic vessels can be distinguished from blood vessels or retraction artifacts. Thus, using immunohistochemical staining, many studies have updated the investigation of the prognostic value of lymphovascular invasion [ 13, 14].
With the identification of specific markers of lymphatic vessels, such as podoplanin/D2–40, LYVE-1, Prox-1 and VEGFR-3, many studies have demonstrated the importance of lymphatic system in tumor metastasis [ 9]. Therefore, we conducted a meta-analysis study not only to estimate the effect of lymphatic microvessel density on patients’ survival, but also to update and re-estimate the prognostic value of lymphovascular invasion in breast cancer.

Methods

Literature search

Databases of PubMed, Embase and Web of Science were searched from inception up to 30 June 2016 by two independent observers. The following Medical Subject Heading (MeSH) terms or keywords were used: “breast cancer OR breast carcinoma OR breast neoplasms” AND “lymphatic vessel density OR lymphatic microvessel density OR LVD OR LMVD OR lymphangiogenesis OR lymphovascular invasion OR lymphatic vessel invasion OR lymphatic invasion OR LVI” AND “prognostic OR prognosis OR survival”. All abstracts mentioned the prognostic values of lymphatic vessel density or lymphovascular invasion, no matter prospective or retrospective, were selected for further consideration.

Inclusion criteria

The studies met the following criteria could be included: (1) treated with the patients with primary breast cancer only, instead of the patients who were previously diagnosed with other diseases; (2) published as a full paper, by no means of review papers, case reports, meeting abstracts, or animal researches; (3) determined lymphovascular invasion presence by immunohistochemical staining, rather than hematoxylin and eosin (H&E) staining. Two independent authors followed the inclusion criteria to review the publications. When two or more articles reported duplicating data, only the study with the most recent data, or the largest dataset was included.

Data extraction

The final eligible studies were conducted the data extraction with a standardized form. The data retrieved from the papers included the first author’s name, year, country, number of the patients (size), age, antibody and its dilution, follow-up period, cutoff value of lymphatic vessel density, detection rate of lymphovascular invasion, and the results of DFS and OS. The key components of designs were used to estimate the quality of primary studies, based on the criteria of the Newcastle-Ottawa Quality Assessment scale (NOS) [ 15].

Statistical analysis

The extracted data were analyzed by using STATA software version 12.0 (STATA Corporation, College Station, Texas, USA). We evaluated the impacts of lymphatic vessel density, lymphovascular invasion on survival by pooling the hazard ratio (HR) results. HR values and their corresponding 95% confidence intervals (95% CIs) were obtained by the methods as previously reported [ 16]. In method one, the HRs were directly acquired from the publications. In method two, the HRs were calculated from the total number of events and its P value, or from the O-E statistic (difference between numbers of observed and expected events) and its variance. In method three, the survival rate at the end point of the survival curve was extracted to reconstruct the estimated HR and its variance, with the assumption that the rate of patients censored was constant during the follow-up period. The estimated HR values were combined into an overall HR value using Peto’s method. Homogeneity test was performed with Q statistic and I 2 statistic. A random-effects model or, in the absence of heterogeneity, a fixed-effects model was applied to combine the HR values. An observed HR > 1 represented a worse survival for the group with a high lymphatic vessel density or presence of lymphovascular invasion. P < 0.05 and I 2 > 50% were considered as statistically significant. Publication bias was evaluated using a funnel plot of Egger’s test.

Results

Study selection process

The literature search result is shown in the flow chart of Fig. 1. We initially identified 1206 potential relevant studies from the databases of PubMed, Embase and Web of Science. After removing the duplicated and irrelevant publications, 208 full-text papers were left over. According to the pre-established inclusion criteria, another 189 papers were excluded because of inappropriate publication types, improper staining methods, or insufficient data. Finally, 19 articles were included within this study.

Characteristics of the included studies

The details of the included 19 studies are exhibited in Tables 1 and 2. A total of 4215 breast cancer patients, aging from 23 to 90 (except one study did not indicate the age [ 13]), were adopted in this study. Different antibodies, including LYVE-1 in one study, podoplanin in four studies, and D2–40 in 14 studies, were used to label the lymphatic vessels. Lymphatic vessel density was determined by counting the number of lymphatic vessels per area at a variable magnification field under a microscope. Lymphovascular invasion was defined as the presence of tumor emboli within a lymphatic vessel lumen, which was detected by immunohistochemical staining rather than H&E staining. DFS was mentioned as the period from the end of primary treatment until any recurrence occurred. OS was defined as the period from primary surgery until the death of patient.
Table 1
Main characteristics and results of the studies evaluating lymphatic microvessel density prognostic values
Author, Year, Country
Size
Age (mean/median, range)
Antibody dilution
Follow-up (month) (mean/median, range)
Cutoff of lymphatic microvessel density
Results
Abe, 2016, Japan [ 24]
91
54 mean (30–81)
D2–40 (1:100)
120 median (8–179)
mean
DFS (+), OS (+)
Bono, 2004, UK [ 17]
180
57 median (34–89)
LYVE-1 1 μg/mL
121.2 median
median
DFS (+), OS (−)
Gu, 2008, China [ 19]
61
57.59 mean (29–90)
podoplanin (1:25)
48.8 mean
median
DFS (+), OS (+)
Mohammed, 2009, UK [ 21]
177
57 median (32–70)
D2–40 (1:100)
96 median (2–184)
median
DFS (+), OS (+)
Mylona, 2007, Greece [ 5]
109
56.89 mean (25–86)
D2–40 (1:20)
96.7 mean (5–135)
median
DFS (+), OS (+)
Nakamura, 2005, Japan [ 6]
113
51 median (24–87)
podoplanin (1:200)
116 median (10–230)
10/mm 2
DFS (+), OS (+)
Tsutsui, 2010, Japan [ 22]
242
58.1 mean (23–86)
D2–40 (1:50)
80.64 median
10.67/field
DFS (+), OS (−)
van der Schaft, 2007, Netherlands [ 18]
121
61.4 mean
Podoplanin (not given)
80.5 mean
median
DFS (+), OS (−)
Zhang, 2008, China [ 20]
70
49 median (30–77)
D2–40 (1:100)
68 median (28–83)
median
DFS (+), OS (+)
Zhao, 2012, China [ 23]
73
53.8 mean (29–75)
D2–40 (1:25)
55 mean (8–73)
median
DFS (+), OS (+)
DFS disease-free survival, OS overall survival
Table 2
Main characteristics and results of the studies evaluating lymphovascular invasion prognostic values
Author, Year, Country
Size
Age (mean/median, range)
Antibody dilution
Follow-up (month) (mean/median, range)
Positive lymphovascular invasion (%)
Results
Arnaout-Alkarain, 2007, Canada [ 26]
303
55.5 mean (26.6–89.7)
D2–40 (0.1 μg/ml)
91.2 median
82/303 (27.1)
DFS (+), OS (+)
El-Gohary, 2008, USA [ 30]
48
64 mean (27–89)
D2–40 (1:50)
DFS 30.6 mean (12–58) OS 55.2 mean (7–84)
18/48 (37.5)
DFS (+), OS (+)
Gudlaugsson, 2011, Norway [ 13]
240
not given
D2–40 (1:200)
117 median (12–192)
51/240 (21.3)
DFS (−), OS (+)
Ito, 2007, Japan [ 27]
69
52.1 mean (27–80)
D2–40 (1:200)
47.5 mean
16/69 (23.2)
DFS (+), OS (−)
Mohammed, 2011, UK [ 31]
1005
54 median (18–75)
D2–40 (1:100)
107.12 mean (1–311)
213/1005 (21.2)
DFS (+), OS (+)
Mohammed, 2014, UK [ 14]
557
52 median (18–72)
D2–40 (1:100)
117 mean (4–246)
262/557 (47.0)
DFS (+), OS (+)
Schoppmann, 2004, Austria [ 25]
374
57.6 median
podoplanin (1:200)
268.4 mean (8–510)
105/374 (28.1)
DFS (+), OS (+)
Tezuka, 2007, Japan [ 28]
132
55.9 median (31–84)
D2–40 (NG)
69 mean
55/132 (41.7)
DFS (+), OS (−)
van der Schaft, 2007, Netherlands [ 18]
121
61.4 mean
Podoplanin (NG)
80.5 mean
not given
DFS (+), OS (−)
Yamauchi, 2007, Japan [ 29]
151
53 mean (28–84)
D2–40 (1:200)
101 median
not given
DFS (+), OS (+)
Zhang, 2008, China [ 20]
70
49 median (30–77)
D2–40 (1:100)
68 median (28–83)
25/70 (35.7)
DFS (+), OS (−)
DFS disease-free survival, OS overall survival

Data analysis

Ten studies [ 5, 6, 1724], involving 1336 patients (sample sizes ranged from 61 to 242), provided sufficient data to evaluate the effects of lymphatic vessel density on DFS and/or OS (Table 1). The lymphatic vessel density of each study was divided into low and high according to the cutoff value. However, the adopted studies have applied different cutoff values, including the median value in seven studies [ 5, 1721, 23], the mean value in one study [ 24], and the actual value in two studies [ 6, 22]. The effects of lymphatic vessel density on DFS and OS were assessed in ten and seven studies, with the pooled HR of 2.02 (95% CIs 1.69 to 2.40, I 2 = 0.0%, P = 0.616) for DFS (Fig. 2) and 2.88 (95% CIs 2.07 to 4.01, I 2 = 0.0%, P = 0.638) for OS (Fig. 3), respectively. According to the median value of follow-up period, the included studies were divided into two subgroups of ≥ median and < median. The detailed results are shown in Figs. 2 and 3.
On the other hand, 11studies [ 13, 14, 18, 20, 2531], involving 3070 patients (sample sizes ranged from 48 to1005), were eligible to evaluate the prognostic value of lymphovascular invasion (Table 2). All of the included studies used the presence of lymphovascular invasion to evaluate its prognostic value. It means that the cutoff value is defined as the presence or not of lymphovascular invasion. And nine of them reported the detection rate of lymphovascular invasion in breast cancer [ 13, 14, 20, 2528, 30, 31]. The detection rates were ranged from 21.2 to 47.0%, with an overall detection rate of 29.56% (827/2798). The effect of lymphovascular invasion on DFS and OS was evaluated in ten and seven studies, respectively. The pooled HRs were 1.81 (95% CIs 1.57 to 2.08, I 2 = 28.8%, P = 0.180) for DFS (Fig. 4) and 1.64 (95% CIs 1.43 to 1.87, I 2 = 35.2%, P = 0.159) for OS (Fig. 5), with no evidence of heterogeneity. According to the median value of follow-up period, the included studies were also divided into two subgroups of ≥ median and < median, which showed no heterogeneity ( P > 0.05) (Figs. 4 and 5).

Sensitivity analysis and publication bias

In order to assess the stability of the results, sensitivity analyses were independently performed in lymphatic vessel density group and lymphovascular invasion group. By removing one study sequentially, sensitivity analyses yielded consistent results, indicating statistically robust results of the analyses (Additional file 1: Figure S1 ). Begg’s tests and the funnel plots of the HR values against the standard error of HR values showed no substantial asymmetry (Additional file 1: Figure S2). There was no evidence of publication bias exhibited in the Egger’s regression test.

Discussion

The current meta-analysis study indicates that both lymphatic vessel density and lymphovascular invasion presence can predict poor prognosis in females with breast cancer. Compared with the high lymphatic vessel density, the presence of lymphovascular invasion in breast cancer appears to have weaker impacts on DFS and OS; but it is also significantly associated with poor survival. Furthermore, lymphovascular invasion was present in 29.56% of breast cancer patients, who would have poorer prognosis.
The metastasis routes of breast cancer consist of local invasion, hematogenous metastasis, and lymphatic metastasis. New blood and lymphatic vessels formed through physiological or pathological processes are called angiogenesis and lymphangiogenesis, respectively. It is well known that tumor angiogenesis, and its indicator blood vessel density are closely associated with the clinicopathological outcomes of breast cancer [ 32]. A meta-analysis study performed by Uzzan et al. has shown that the high blood vessel density can predict poor survival in breast cancer (risk ratio = 1.54 for DFS and OS with the same 95% CI 1.29–1.84) [ 9]. However, the prognostic value of lymphatic vessel density is still uncertain [ 33]. With the development of lymphatic vessel biology, lymphatic vascular system has been considered as an active player involved in breast cancer [ 34]. Our meta-analysis result shows that high lymphatic vessel density has unfavorable impacts on DFS (HR 2.02, 95% CI 1.69 to 2.40) and OS (HR 2.88, 95% CI 2.07 to 4.01). Compare with blood vessel density, lymphatic vessel density even displays a stronger predictive value in breast cancer.
The result that lymphatic vessel density is a risk factor of poor survival is supported by all included studies; however, the values of lymphatic vessel density were differentiated notably in these studies [ 17, 21, 24]. The variation might be caused by patient sources, staining techniques, antibody categories and antibody dilutions. In addition, different counting methods of lymphatic vessel density, by using different hotspots (three [ 19], four [ 18], and five [ 24]), magnification field (100× [ 22], 200× [ 24], 400× [ 19]), and measuring unit (vessels/mm2 [ 24], vessels/area [ 22]), are also accounted for the variation of results. Furthermore, the cutoff value to divide lymphatic vessel density as low and high is a crucial factor that cannot be ignored. Because the asset value of lymphatic vessel density is not a normal distribution, seven in ten studies chose the median value as the cutoff value, other three studies took the mean or actual value as the cutoff value. Therefore, studies with more standardized and stricter design are required in the assessment of lymphatic vessel density.
Due to lack of the specific markers of lymphatic endothelium cells, most of the previous studies have detected lymphovascular invasion using H&E staining method [ 11, 12]. One major challenge of this method is to distinguish lymphovascular invasion from retraction artifacts caused by tissue handling and fixation on H&E stained sections. Another challenge is that lymphovascular invasion may be missed if tumor cells are packed in a small vessel [ 35]. With the help of specific markers, such as D2–40/podoplanin, LYVE-1, VEGFR-3, and Prox-1, lymphatic vessels can be effectively distinguished from blood vessels or retraction artifacts. A previous study has compared the reliability of immunohistochemical staining with that of H&E staining [ 36]. The results showed that the detection rate of lymphovascular invasion widely ranged from 10 to 49% for H&E staining; however, the range was narrower using immunohistochemical staining (ranged from 21 to 42%) [ 36]. It indicates that immunohistochemical staining should be more reliable for identifying lymphovascular invasion. Therefore, we conducted a meta-analysis to study the prognostic value of lymphovascular invasion, which was assessed by immunohistochemical staining instead of H&E staining [ 35].
With the accumulating evidence, we conducted an update meta-analysis study to re-evaluate the prognostic value of lymphovascular invasion. The result shows that lymphovascular invasion, detected by immunohistochemical staining, has an unfavorable impact on survival, in line with the previous study [ 36]. However, the result should be analysed more thoroughly. Mohammed et al. [ 14, 31] has demonstrated that the impact of lymphovascular invasion is mainly found in breast cancer patients with negative lymph node metastasis and with a single positive lymph node metastasis. Moreover, the frequency of lymphovascular invasion per tumor lesion has no effects on prognosis in lymph node negative and lymph node positive patients [ 14, 31]. Besides, the location of lymphovascular invasion [ 23, 30] and the patients’ age [ 25] also have influence on the survival of breast cancer patients.
The current meta-analysis study has some strengths. The results show that both lymphatic vessel density and lymphovascular invasion are unfavorable predictors on DFS and OS in breast cancer. The included 19 studies and 4215 participants enhanced the statistical power and provided more reliable results. However, some limitations should be considered. All included studies were observational studies with relatively small sample sizes. Selection bias and recall bias were inevitable. Besides, the values of lymphatic vessel density varied notably due to unmeasured or inadequately measured factors. It resulted that different cutoff values were used to define high and low lymphatic vessel density subgroups in different studies. Although there are no heterogeneities show in each subgroup, the deviations caused by different cutoff values cannot be ignored. Nevertheless, the conclusion that higher lymphatic vessel density is associated with poor survival is reasonable even with different cutoff values. Therefore, strictly controlled studies with larger sample sizes are needed.

Conclusions

The study demonstrates that the high lymphatic vessel density and the presence of lymphovascular invasion both are unfavorable prognostic factors in primary breast cancer. Compared with lymphatic vessel density, lymphovascular invasion shows a weaker influence on patients’ survival, but it is also an important risk factor in breast cancer. Counting methods of lymphatic vessel density, choice of appropriate cutoff value, thoroughly analysis of lymphovascular invasion, and standardized design of study, are the crucial points need to be considered.

Acknowledgements

None to declare.

Funding

The work was supported by the National Natural Science Foundation of China (NSFC) (Nos 81401466, 81501521).

Availability of data and materials

All data generated or analysed during this study are included in this published article.

Authors’ contributions

ZLG designed the study, prepared the final version and submitted the paper. ZS made the literature search and drafted the manuscript. ZD and GMF extracted the study data and made the statistical analysis. WL and LCW corrected the draft of the paper and prepared the final version of the manuscript. All authors contributed to the design of this meta-analysis and played a substantial contribution in manuscript redaction. All authors approved the final version of this article.

Competing interests

The authors declare that they have no competing interests.

Consent for publication

Not applicable.

Ethics approval and consent to participate

Not applicable.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License ( http://​creativecommons.​org/​licenses/​by/​4.​0/​), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated.
Zusatzmaterial
Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 1/2017

BMC Cancer 1/2017 Zur Ausgabe

Neu im Fachgebiet Onkologie

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Onkologie und bleiben Sie gut informiert – ganz bequem per eMail.

Bildnachweise